PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|March 17, 2016
ANGUS Unveils a New Division
Author(s)Pharmaceutical Technology Editors
ANGUS reveals ANGUS Life Sciences as a new company division that will serve pharmaceutical, biotechnology, and agriculture markets.
Advertisement
ANGUS Chemical Company, a manufacturer and marketer of nitroalkanes and their derivatives, announced on March 14, 2016 the launch of its new life-sciences division, ANGUS Life Sciences. ANGUS Life Sciences supplies customers in the biotechnology, pharmaceutical, and agriculture markets with buffers, biochemicals, biomolecules, and intermediates.
Based in the US, ANGUS Life Sciences is a fully integrated manufacturer of TRIS AMINO buffers, based on their nitroalkane chemistry. In addition to TRIS AMINO, ANGUS Life Sciences also provides other offerings, including biological buffers, biochemicals, biomolecules, and amino acids.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement